安琪酵母(600298) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥3,031,758,910.32, representing a year-on-year increase of 14.14%[4] - The net profit attributable to shareholders decreased by 29.30% to ¥312,536,640.64 compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 36.09% to ¥264,745,470.60[4] - Basic earnings per share decreased by 29.30% to ¥0.3793[4] - Diluted earnings per share also decreased by 29.36% to ¥0.3789[5] - The net profit for Q1 2022 was CNY 316,921,262.65, a decrease of 29.4% compared to CNY 449,243,533.21 in Q1 2021[19] - The total operating profit for Q1 2022 was CNY 387,232,849.54, down 26.7% from CNY 528,127,223.26 in the same period last year[19] - The total comprehensive income attributable to the parent company was CNY 312,536,640.64, a decrease of 29.2% from CNY 442,051,717.10 in Q1 2021[20] - The net profit margin for Q1 2022 was approximately 11.14%, compared to 10.00% in Q1 2021, indicating improved profitability[18] Cash Flow - The net cash flow from operating activities increased by 29.70% to -¥312,503,084.88, primarily due to increased cash receipts from sales of goods and services[8] - Cash inflow from operating activities totaled CNY 3,166,536,867.13, compared to CNY 2,674,171,849.76 in Q1 2021, reflecting a growth of 18.4%[21] - Cash outflow from operating activities was CNY 3,479,039,952.01, an increase from CNY 3,118,684,805.13 in Q1 2021[21] - The cash flow from operating activities showed a net outflow of CNY -312,503,084.88, an improvement from CNY -444,512,955.37 in Q1 2021[21] - Cash inflow from financing activities was CNY 1,548,800,000.00, up from CNY 1,029,246,000.00 in Q1 2021, marking an increase of approximately 50.5%[31] - The total cash outflow from financing activities was CNY 1,916,574,923.85, compared to CNY 1,443,106,975.94 in the same quarter of the previous year, representing an increase of approximately 32.8%[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥14,018,807,642.89, an increase of 4.26% from the end of the previous year[5] - The total liabilities increased to ¥6,474,485,057.13, up from ¥6,244,622,116.15, reflecting a rise of 3.68%[16] - The total equity attributable to shareholders rose to ¥7,192,973,229.21, an increase of 4.94% from ¥6,854,060,616.17[16] - Current assets totaled ¥6,705,716,291.88, an increase from ¥5,956,320,671.58, marking a growth of about 12.5%[24] - Total assets increased to ¥10,831,135,646.35, up from ¥9,973,385,406.85 year-over-year, representing an increase of approximately 8.6%[24] Operational Highlights - The company achieved operating revenue of 3.032 billion yuan in Q1 2022, representing a year-on-year growth of 14.14%[12] - The total operating costs for Q1 2022 were ¥2,694,590,107.47, up from ¥2,151,118,275.01 in Q1 2021, reflecting a growth of 25.38%[18] - Employee compensation decreased by 62.09% compared to the end of the previous year, primarily due to the distribution of year-end bonuses in Q1 2022[9] - Financial expenses increased by 326.23% year-on-year, mainly due to increased interest expenses and exchange losses[9] - Interest income rose by 118.70% year-on-year, attributed to higher interest income from bank deposits[9] - The company received government subsidies, leading to a 90.30% increase in other income compared to the same period last year[9] - Export revenue grew by 16.37% year-on-year, supported by the company's six overseas divisions adapting to local markets[12] - The company is focusing on industrial clients and has seen over 20% growth in microbial and plant nutrition sectors[12] Inventory and Receivables - Accounts receivable increased by 32.61% due to increased sales[8] - Accounts receivable increased to ¥1,489,810,972.16, up 32.66% from ¥1,123,486,481.32 in the previous year[14] - Inventory levels rose to ¥2,443,012,591.20, an increase of 8.55% compared to ¥2,251,008,149.60 in the previous year[14] - The company reported a decrease in inventory to ¥627,368,285.06 from ¥585,602,436.88, a decline of about 7.1%[24] Research and Development - The company's R&D expenses for Q1 2022 were ¥119,850,888.67, which is a 15.99% increase from ¥103,354,261.02 in Q1 2021[18] - Research and development expenses for Q1 2022 were ¥63,232,524.16, compared to ¥59,193,947.68 in Q1 2021, reflecting an increase of about 6.9%[26] Shareholder Actions - The company plans to proceed with a non-public offering of shares as approved by the China Securities Regulatory Commission[13]